



## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Richard Gorlick, M.D.

Committee: Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (PedsODAC)

Meeting Date: June 17, 2020

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: information will be presented regarding pediatric development plans for two products that are in development for an adult oncology indication. The subcommittee will consider and discuss issues relating to the development of each product for pediatric use and provide guidance to facilitate the formulation of Written Requests for pediatric studies, if appropriate. The product under consideration, relevant to the waiver, is SP 2577, application presentation by Salariaus Pharmaceuticals, Inc., I may be considered for participation in the advisory committee meeting described above.

| <u>Type of Interest</u>      | <u>Nature</u>  | <u>Magnitude</u>              |
|------------------------------|--|-------------------------------|
| I. Personal/Immediate Family |  |                               |
| None                         |  |                               |
| II. Other Imputed Interests  |  |                               |
| contract/grant               | National Pediatric Cancer Foundation, unrelated entity | \$ (b) (4) – \$ (b) (4) total |

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/s/\_\_\_\_\_  
Signature

5/28/20  
Date